The effect of vitamin K supplementation on anticoagulant treatment by Rombouts, E.K. et al.
5 Blinder D, Manor Y, Martinowitz U, Taicher S. Dental extractions in
patients maintained on oral anticoagulant therapy: comparison of INR
value with occurrence of postoperative bleeding. Int J Oral Maxillofac
Surg 2001; 30: 518–21.
6 Evans IL, Sayers MS, Gibbons AJ, Price G, Snooks H, Sugar AW.
Can warfarin be continued during dental extraction? Results of a
randomized controlled trial. Br J Oral Maxillofac Surg 2002; 40: 248–
52.
7 Devani P, Lavery KM, Howell CJ. Dental extractions in patients on
warfarin: is alteration of anticoagulant regime necessary? Br J Oral
Maxillofac Surg 1998; 36: 107–11.
8 Wahl MJ. Myths of dental surgery in patients receiving anticoagulant
therapy. J Am Dent Assoc 2000; 131: 77–81.
The effect of vitamin K supplementation on anticoagulant
treatment
E . K . ROMBOUTS ,* F . R . ROSENDAAL* and F . J . M . VAN DER MEER*
*Department of Hematology, Leiden University Medical Center, the Netherlands; and Department of Clinical Epidemiology, Leiden University
Medical Center, the Netherlands
To cite this article: Rombouts EK, Rosendaal FR, van der Meer FJM. The effect of vitamin K supplementation on anticoagulant treatment. J Thromb
Haemost 2006; 4: 691–2.
Until recently, the view that dietary vitamin K interferes with
oral anticoagulant therapy was based on case reports and a few
small experimental studies with extremely high vitamin K
intake. In two recent studies the effect of dietary vitamin K on
oral anticoagulation was systematically investigated [1,2].
These studies showed that, even in patients on an average diet,
changes in vitamin K intake affect anticoagulation. When
patients decreased their vitamin K intake the International
Normalized Ratio (INR) response was more pronounced than
when vitamin K intake was increased [2]. Because changes are
proportionally larger in people with a low average vitamin K
intake, it is likely that the INR is more sensitive to a varying
vitamin K intake in those individuals. Sconce et al. established
that daily intake of vitaminKwas indeed lower in patients with
unstable anticoagulation than in stably anticoagulated patients
[3]. Daily supplementation of low doses of vitamin K might
thus be beneﬁcial.
To safely start vitamin K supplementation in patients
receiving oral anticoagulants, it is important to know the
effect of low doses of vitamin K on the INR and on the dose
of the anticoagulant drug. The dose–response relationship of
vitamin K supplementation on the INR in healthy subjects
who received a ﬁxed dose of oral anticoagulants was
established by Schurgers et al. [4]. They concluded that
100 lg of vitamin K daily did not signiﬁcantly interfere with
oral anticoagulant therapy. Consequently, Oldenburg sug-
gested 100 lg vitamin K as a recommended supplementation
dose in his editorial [5]. However, Kurnik et al. found that, in
patients with a low vitamin K status, even daily supplement
doses as low as 25 lg led to an important reduction of the
INR [6].
We performed a pilot study to determine the effect of
escalating daily doses of vitamin K on the required dose of the
anticoagulant drug phenprocoumon. We included patients
from the Leiden Anticoagulation Clinic who took part in a
program for self-management of anticoagulant treatment. The
total study period was 9 weeks, in which the INR was
measured at least 3 times a week with a CoaguCheck S
coagulometer (Roche Diagnostics, Almere, Netherlands).
Patients received vitamin K for 3 weeks. The ﬁrst and last
3 weeks served as control periods. Five patients received 50 lg
and 10 patients 100 lg of oil-based vitamin K1 (250 lg g)1).
The primary endpoint was the percentage change in phenpro-
coumon dose during and after vitamin K needed to keep the
INR within therapeutic limits.
Supplementation of 50 lg vitamin K had little effect on
the INR and therefore only slight dose-adjustments were
made (mean dose increase after starting vitamin K 3% [95%
conﬁdence interval (CI95): )4% to 10%]. Supplementation
of 100 lg resulted in a mean dose increase of 9% (CI95: 0–
19%, Fig. 1). There was considerable inter-individual vari-
ability in response with dose adjustments ranging from )7%
to 37%. In the three weeks of follow-up after the vitamin K
was discontinued phenprocoumon doses were lowered to pre-
substitution values (mean change of )7%, CI95: )15% to
0%).
Our results show that daily supplementation up to 100 lg
can be given without a relevant decrease in the INR, on the
condition of frequent monitoring during and after the supple-
mentation to allow timely dose adjustments.
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The acute phase response (APR) is a systemic response to local
inﬂammatory processes elicited by infection and/or other types
of tissue injury [1,2]. It serves to limit the eﬀect of damaging
agents by inducing a largely cytokine-mediated series of
systemic events, such as fever, altered metabolism, changes in
concentrations of a series of blood proteins (acute phase
proteins), and changes in vascular permeability and hemato-
logic parameters. Mainly tumor necrosis factor (TNF)-a,
interleukin (IL)-6 and IL-1 induce the changes in synthesis of
acute phase proteins. Intravenous injection of endotoxin
provides a highly controlled model to investigate the APR
[3]. Studies of patients with sepsis and of in vivo endotoxin
challenge of healthy subjects have shown that the APR
promotes thrombin generation as reﬂected by an increased
formation of thrombin–antithrombin complex and prothrom-
bin fragment 1 + 2 [4–6]. Levels of the anticoagulant proteins;
tissue factor pathway inhibitor, protein C and antithrombin are
often decreased in patients exhibiting an APR, mainly because
of increased consumption of these three proteins [4,5]. In the
model of human endotoxemia the levels of antithrombin and
tissue factor pathway inhibitor are not or only slightly aﬀected,
whereas protein C levels decrease about 15% partly or wholly
as a result of thrombin-catalyzed conversion of protein C to
activated protein C [5,7]. The anticoagulant protein, protein S
is an essential cofactor to activated protein C in the inactivation
of factors Va and VIIIa [8]. Eﬀective enhancement of activated
protein C-mediated inactivation of factor VIIIa by protein S
requires the presence of FV. About 60% of protein S forms an
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Fig. 1. Eﬀect of vitamin K substitution on the mean International
Normalized Ratio (INR) (d) and the mean phenprocoumon dose ( ) in
10 patients receiving 100 lg vitamin K daily.
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